Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Rhea-AI Summary
Black Diamond Therapeutics (Nasdaq: BDTX) will host a live webcast on Wednesday, December 3, 2025 at 8:00am ET to present results from its Phase 2 clinical trial of silevertinib and to provide a program update.
Investors can access the webcast under “Events and Presentations” in the Investors section at www.blackdiamondtherapeutics.com. A replay will be available after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BDTX declined 8.49%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.6% during that session. Argus tracked a trough of -37.8% from its starting point during tracking. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $19M from the company's valuation, bringing the market cap to $205M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with CCCC down 1.55% while ELTX, KYTX, NTHI, and NVCT are up between 2.57% and 6%, suggesting stock-specific trading in BDTX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Clinical data update | Positive | -22.0% | Preliminary Phase 2 silevertinib data with strong ORR and CNS ORR metrics. |
| Dec 02 | Webcast announcement | Neutral | -8.5% | Announcement of webcast to present Phase 2 silevertinib results and update. |
| Nov 06 | Conference participation | Neutral | -2.3% | Planned participation in multiple investor conferences with webcast access. |
| Nov 06 | Earnings and update | Neutral | +2.8% | Q3 2025 results and guidance on upcoming silevertinib efficacy readouts. |
| Aug 07 | Earnings and pipeline | Positive | -15.2% | Q2 2025 results with improved net loss and completed silevertinib enrollment. |
Recent clinically focused and corporate updates often saw negative price reactions, even when developments appeared operationally positive.
Over the last six months, Black Diamond Therapeutics has focused on advancing silevertinib and maintaining its financial runway. Earnings updates in Q2 2025 and Q3 2025 highlighted cash positions above $135.5M and net losses in the single‑digit millions per quarter, yet shares often traded down afterward. Clinical milestones, including completing enrollment in the n=43 Phase 2 NSCLC trial and later reporting preliminary Phase 2 data, also coincided with notable selloffs. Today’s webcast scheduling continues this pattern of frequent investor communications around the silevertinib program.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 13, 2025 allows Black Diamond to offer up to $500,000,000 in various securities, including an at-the-market program of up to $150,000,000 in common stock. This provides flexibility to raise capital over time, with proceeds earmarked for R&D, clinical development, working capital, and capital expenditures.
Market Pulse Summary
The stock moved -8.5% in the session following this news. A negative reaction despite this being only a webcast notice would fit past patterns where even constructive updates preceded selling. Prior clinical and earnings communications sometimes saw sharp drawdowns. The existing $500,000,000 shelf registration and potential use of an at-the-market program up to $150,000,000 may also have weighed on sentiment, as investors balanced dilution risk against the value of the forthcoming Phase 2 silevertinib data.
Key Terms
phase 2 clinical trial medical
oncogenic mutations medical
AI-generated analysis. Not financial advice.
Webcast to be held Wednesday, December 3, at 8:00am ET
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.
Webcast information
The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.
Contact
For Investors:
investors@bdtx.com
For Media:
media@bdtx.com
FAQ
When will Black Diamond Therapeutics (BDTX) present Phase 2 silevertinib results?
How can investors access the BDTX webcast for silevertinib results on December 3, 2025?
Will a replay of the BDTX December 3, 2025 webcast be available?
What will Black Diamond cover in the December 3, 2025 webcast about silevertinib?
Is the December 3, 2025 BDTX presentation focused on clinical data or corporate strategy?
